Related Experiment Video
Updated: Mar 24, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer
Gaëlle Judes1, Khaldoun Rifaï1, Marine Daures1
1Department of Oncogenetics, Centre Jean Perrin, CBRV, 28 place Henri-Dunant, 63001, Clermont-Ferrand, France; EA 4677 "ERTICA", University of Auvergne, 63011, Clermont-Ferrand, France.
Abstract:
Triple negative breast cancer (TNBC) represents about 15% to 20% of all breast cancers and is typically associated with poorer outcome than other breast cancer subtypes. The heterogeneity of this breast cancer subtype and present lack of clinically established targeted therapies further complicates treatment of patients. The treatment of TNBC emphasizes enhancing health care and developing personalized medicine. To respond to this need, the researchers have turned their attention to a different approach to scientific enquiry: the era of "big biology" and the integrative study of biological systems, also called "Omics" technologies. The term omics comprises different fields of molecular studies and characterizes a global view on biological molecules such as DNA, RNA, proteins, and metabolites. Combined "omics" approach offers a major tool for the understanding of a challenging cancer model, TNBC. This review discusses the different discoveries made using omics technologies concerning the molecular mechanisms underlying TNBC phenotypic heterogeneity, and their potential transfer to clinical applications.
Insights
Triple negative breast cancer (TNBC) is aggressive and hard to treat due to its complexity. Omics technologies offer new insights into TNBC
Area of Science:
- Oncology and Molecular Biology
Background:
- Triple negative breast cancer (TNBC) accounts for 15-20% of breast cancers, presenting a poorer prognosis.
- TNBC's heterogeneity and lack of targeted therapies challenge effective patient treatment.
- Personalized medicine and enhanced healthcare are key goals for TNBC management.
Purpose of the Study:
- To review discoveries from omics technologies in understanding TNBC.
- To explore the molecular mechanisms behind TNBC's phenotypic heterogeneity.
- To assess the clinical application potential of omics-derived findings in TNBC.
Main Methods:
- Utilizing "omics" technologies for an integrative study of biological systems.
- Analyzing DNA, RNA, proteins, and metabolites for a global molecular view.
- Reviewing existing research on omics applications in TNBC.
Main Results:
- Omics approaches provide a powerful tool for dissecting complex cancer models like TNBC.
- Discoveries highlight molecular mechanisms driving TNBC heterogeneity.
- Identification of potential biomarkers and therapeutic targets.
Conclusions:
- Omics technologies are crucial for unraveling TNBC's molecular complexity.
- Findings pave the way for personalized medicine strategies in TNBC treatment.
- Translating omics discoveries into clinical applications is a promising avenue for improving patient outcomes.
